by Tony Akiwumi | Oct 30, 2025 | Pharma / Market Access
In one market access workshop, a payer representative once said to a biotech team, “Your data are excellent. They just don’t answer any of our questions.” The silence that followed summed up a familiar problem: great science, misaligned evidence. The gap between...
by Tony Akiwumi | Oct 30, 2025 | Pharma / Market Access
When I joined a cross-functional launch team for a rare oncology therapy, I remember a patient advocate standing up in the room and saying, “You keep talking about access. But you’re not listening to the people who need it.” The silence that followed was...
by Tony Akiwumi | Oct 29, 2025 | Pharma / Market Access
Artificial intelligence has entered every corner of pharmaceutical development — discovery, clinical design, safety, and supply chain. Yet its most profound potential may lie in the least glamorous area: market access. AI could fundamentally change how we understand...
by Tony Akiwumi | Oct 29, 2025 | Pharma / Market Access
The phrase “regulatory strategy” often conjures images of submission deadlines, data packages, and procedural checklists. Yet the most effective regulatory relationships are not transactional; they are relational. They are built through dialogue, transparency, and...
by Tony Akiwumi | Oct 29, 2025 | Pharma / Market Access
A few years ago, a journalist asked a question at a press briefing that silenced the room: “If this drug saves lives, why does it cost more than a house?” The company’s spokesperson answered with rehearsed lines about R&D costs, risk, and value-based pricing....
